These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14554007)

  • 21. Proteasome inhibition measurements: clinical application.
    Lightcap ES; McCormack TA; Pien CS; Chau V; Adams J; Elliott PJ
    Clin Chem; 2000 May; 46(5):673-83. PubMed ID: 10794750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
    Cusack JC
    Cancer Treat Rev; 2003 May; 29 Suppl 1():21-31. PubMed ID: 12738240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    An WG; Hwang SG; Trepel JB; Blagosklonny MV
    Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
    Fleming JA; Lightcap ES; Sadis S; Thoroddsen V; Bulawa CE; Blackman RK
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1461-6. PubMed ID: 11830665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
    Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
    Mitra-Kaushik S; Harding JC; Hess JL; Ratner L
    Blood; 2004 Aug; 104(3):802-9. PubMed ID: 15090453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
    Tan C; Waldmann TA
    Cancer Res; 2002 Feb; 62(4):1083-6. PubMed ID: 11861386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
    Princiotta MF; Schubert U; Chen W; Bennink JR; Myung J; Crews CM; Yewdell JW
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):513-8. PubMed ID: 11149939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical update: proteasome inhibitors in hematologic malignancies.
    Richardson P
    Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
    Giuliano M; D'Anneo A; De Blasio A; Vento R; Tesoriere G
    Ital J Biochem; 2003 Jun; 52(2):112-21. PubMed ID: 14677428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2004 Jan; 145(2):67-74. PubMed ID: 14978877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.
    Adams J; Behnke M; Chen S; Cruickshank AA; Dick LR; Grenier L; Klunder JM; Ma YT; Plamondon L; Stein RL
    Bioorg Med Chem Lett; 1998 Feb; 8(4):333-8. PubMed ID: 9871680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Kelley TW; Alkan S; Srkalovic G; Hsi ED
    Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition enhances lipofuscin formation.
    Terman A; Sandberg S
    Ann N Y Acad Sci; 2002 Nov; 973():309-12. PubMed ID: 12485885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The proteasome: structure, function, and role in the cell.
    Adams J
    Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.